For the year ending 2025-12-31, MGRX made $456,021 in revenue. -$21,818,994 in net income. Net profit margin of -4784.65%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenues | 456,021 | |||
| Cost of revenues | 54,422 | |||
| Cost of revenues - related party | 151,213 | |||
| Gross profit | 250,386 | |||
| General and administrative expenses | 3,756,373 | |||
| Salary and benefits | 1,348,051 | |||
| Advertising and marketing | 822,860 | |||
| Investor relations | 1,561,206 | |||
| Stock based compensation | 10,794,245 | |||
| Total operating expenses | 18,282,735 | |||
| Loss from operations | -18,032,349 | |||
| Interest expense | 103,513 | |||
| Amortization of intangible assets | 1,122,639 | |||
| Impairment of license agreement | 1,239,942 | |||
| Loss from settlement | -125,624 | |||
| Loss from debt extinguishment - related parties | -19,388 | |||
| Total other (income) expense | -2,611,106 | |||
| Loss before income taxes | -20,643,455 | |||
| Net loss | -20,643,455 | |||
| Net loss attributed to non-controlling interest | -461 | |||
| Net loss attributed to mangoceuticals, inc | -20,642,994 | |||
| Preferred stock dividend requirements | 1,176,000 | |||
| Net loss attributed to mangoceuticals, inc. common stockholders | -21,818,994 | |||
| Basic EPS | -2.17 | |||
| Diluted EPS | -2.17 | |||
| Basic Average Shares | 10,071,609 | |||
| Diluted Average Shares | 10,071,609 | |||
MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC. (MGRX)